The Medical Innovation Agenda for the 119th Congress

WASHINGTON—AdvaMed® announced today that nominations for its 2025 Lifetime Achievement Award as well as the AdvaMedDx Lifetime of Leadership & Service Award and the AdvaMed Imaging Röntgen Award are open through April 10. All three of these annual awards will be presented during The MedTech Conference, Oct.18-21, 2026, in Boston. 

WASHINGTON—AdvaMed, the Medtech Association, today welcomed Senate approval of legislation reauthorizing the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs and urged the House of Representatives to act swiftly on passage.

TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment. The technology received Breakthrough Device designation from the FDA and is designed to enhance surgeons’ ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for re-operations.

AdvaMed 2025 Membership Has Its Privileges highlights major legislative and regulatory wins delivering millions in savings and new revenue for members.

Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.

Join AdvaMed for an exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS Model. Attendees will gain critical insights into model performance metrics, payment pathways, and opportunities for the MedTech industry.

HALIFAX, NS, Feb. 24, 2026 /PRNewswire/ – ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the completion of patient enrollment in its pivotal U.S. FDA Investigational Device Exemption (IDE) study, ROUTE90. The study evaluates Eye90 microspheres®, a novel Yttrium-90 (Y90) radioembolization device, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

ATRO Medical, the Dutch clinical-stage orthopedic company developing a novel artificial meniscus implant for patients suffering from post-meniscectomy pain, today announces the successful closing of a €3 million financing round. The financing round is primarily composed of equity investments, complemented by non-dilutive funding. It brings together MedTech investors from the Netherlands, Switzerland, and the United Arab Emirates such as 819 Capital, Thuja Capital, Bolwork International Investment and industry leaders DSM-Firmenich Ventures and Samaplast.